Sec Form 4 Filing - ROTHBLATT MARTINE A @ UNITED THERAPEUTICS Corp - 2022-11-03

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ROTHBLATT MARTINE A 2. Issuer Name and Ticker or Trading Symbol UNITED THERAPEUTICS Corp [ UTHR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CHAIRPERSON & CEO (Last) (First) (Middle) C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET 3. Date of Earliest Transaction (MM/DD/YY) 11/03/2022 (Street) SILVER SPRING, MD20910 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 11/03/2022 M( 1 ) 8,000 A $ 113.08 8,130 D Common Stock 11/03/2022 S( 1 ) 242 D $ 255.0093( 2 ) 7,888 D Common Stock 11/03/2022 S( 1 ) 290 D $ 257.381( 3 ) 7,598 D Common Stock 11/03/2022 S( 1 ) 487 D $ 259.3128( 4 ) 7,111 D Common Stock 11/03/2022 S( 1 ) 1,191 D $ 260.3011( 5 ) 5,920 D Common Stock 11/03/2022 S( 1 ) 615 D $ 261.1864( 6 ) 5,305 D Common Stock 11/03/2022 S( 1 ) 512 D $ 262.1761( 7 ) 4,793 D Common Stock 11/03/2022 S( 1 ) 267 D $ 263.4753( 8 ) 4,526 D Common Stock 11/03/2022 S( 1 ) 546 D $ 264.889( 9 ) 3,980 D Common Stock 11/03/2022 S( 1 ) 700 D $ 265.8935( 10 ) 3,280 D Common Stock 11/03/2022 S( 1 ) 963 D $ 267.8056( 11 ) 2,317 D Common Stock 11/03/2022 S( 1 ) 266 D $ 268.7898( 12 ) 2,051 D Common Stock 11/03/2022 S( 1 ) 390 D $ 269.6762( 13 ) 1,661 D Common Stock 11/03/2022 S( 1 ) 1,531 D $ 266.8248( 14 ) 130 D Common Stock 11/04/2022 M( 1 ) 8,000 A $ 113.08 8,130 D Common Stock 11/04/2022 S( 1 ) 397 D $ 262.8402( 15 ) 7,733 D Common Stock 11/04/2022 S( 1 ) 4,144 D $ 264.2064( 16 ) 3,589 D Common Stock 11/04/2022 S( 1 ) 2,098 D $ 264.9937( 17 ) 1,491 D Common Stock 11/04/2022 S( 1 ) 335 D $ 266.182( 18 ) 1,156 D Common Stock 11/04/2022 S( 1 ) 767 D $ 267.3493( 19 ) 389 D Common Stock 11/04/2022 S( 1 ) 259 D $ 267.9474( 20 ) 130 D Common Stock 166 I By Spouse Common Stock 651,549 I By Trusts

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transac tion Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options $ 113.08 11/03/2022 M( 1 ) 8,000 12/31/2013 12/31/2023 Common Stock 8,000 $ 0 992,000 D Stock Options $ 113.08 11/04/2022 M( 1 ) 8,000 12/31/2013 12/31/2023 Common Stock 8,000 $ 0 984,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ROTHBLATT MARTINE A C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING, MD20910 X CHAIRPERSON & CEO Signatures /s/ John S. Hess, Jr., under Power of Attorney 11/04/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023. ( 2 )This transaction was executed in multiple trades at prices ranging from $254.99 to $255.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 3 )This transaction was executed in multiple trades at prices ranging from $257.10 to $257.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 4 )This transaction was executed in multiple trades at prices ranging from $258.73 to $259.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 5 )This transaction was executed in multiple trades at prices ranging from $259.75 to $260.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 6 )This transaction was executed in multiple trades at prices ranging from $260.80 to $261.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 7 )This transaction was executed in multiple trades at prices ranging from $261.82 to $262.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 8 )This transaction was executed in multiple trades at prices ranging from $263.00 to $263.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 9 )This transaction was executed in multiple trades at prices ranging from $264.11 to $265.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 10 )This transaction was executed in multiple trades at prices ranging from $265.34 to $266.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 11 )This transaction was executed in multiple trades at prices ranging from $267.37 to $268.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 12 )This transaction was executed in multiple trades at prices ranging from $268.43 to $269.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 13 )This transaction was executed in multiple trades at prices ranging from $269.43 to $270.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 14 )This transaction was executed in multiple trades at prices ranging from $266.37 to $267.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 15 )This transaction was executed in multiple trades at prices ranging from $262.19 to $263.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 16 )This transaction was executed in multiple trades at prices ranging from $263.62 to $264.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 17 )This transaction was executed in multiple trades at prices ranging from $264.63 to $265.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 18 )This transaction was executed in multiple trades at prices ranging from $265.69 to $266.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 19 )This transaction was executed in multiple trades at prices ranging from $266.80 to $267.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. ( 20 )This transaction was executed in multiple trades at prices ranging from $267.86 to $268.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.